Pretomanid (PA-824)

05/20

ALTERNATE NAMES: (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (3S)-8-nitro-3-[[4-(trifluoromethoxy)phenyl]methoxy]-5-oxa-1,7-diazabicyclo[4.3.0]nona-6,8-diene

CATALOG #:

B3033-5	5 mg
B3033-25	25 mg

STRUCTURE:



MOLECULAR FORMULA: $C_{14}H_{12}F_3N_3O_5$

MOLECULAR WEIGHT: 359.26

CAS NUMBER: 187235-37-6

APPEARANCE: White to Pale Yellow Solid

PURITY: ≥95%

SOLUBILITY: ~5 mg/ml in DMSO (may need warming or ultrasonication)

DESCRIPTION: Pretomanid is a nitroimidazopyran active againt *Mycobacterium tuberculosis*. It is active against multidrug-resistant *M. tuberculosis* clinical isolates with MIC <1 µg/ml. Pretomanid at 25, 50, and 100 mg/kg of body weight daily for 10 days or 60 days reduces the mycobacterial burden in both spleen and lung tissue in a mouse infection model. Pretomanid at 100 mg/kg in cyclodextrin/lecithin reduces the bacterial load below 500 CFU in the lungs and spleen. It is approved for use in combination treatment for drug-resistant, treatment-intolerant or non-responsive multidrug-resistant (MDR) Tuberculosis.

STORAGE TEMPERATURE: -20ºC

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Lenaerts, A.J., Gruppo, V., Marietta, K.S., et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49(6), 2294-2301 (2005).
2. Keam. S.J. Pretomanid: First Approval. Drugs. 79(16):1797-1803 (2019).

RELATED PRODUCTS:

Ertapenem sodium (Cat. No. B3024)
Gramicidin A (Cat. No. B2967)
Amphotericin B, USP (Cat. No. 2497)
Anidulafungin (Cat. No. B2966)
Ampicillin sodium (Cat. No. 2484)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***